FindTrial
Sign In

Exploration of an accurate screening and a dynamic monitoring model of the efficacy of plasma cell clonal diseases based on big data from multiple sources of testing.

Exploration of an accurate screening and a dynamic monitoring model of the efficacy of plasma cell clonal diseases based on big data from multiple sources of testing.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094509
Enrollment
Unknown
Registered
2024-12-24
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma is a malignant tumour caused by the abnormal proliferation of plasma cells in the bone marrow that secrete monoclonal immunoglobulins or fragments thereof (M proteins), resulting in a variety of clinical manifestations including extensive bone destruction, recurrent infections, anaemia, hypercalcemia, hyperviscosity syndrome and renal insufficiency.

Interventions

M protein positive group:None
M protein negative group:None

Sponsors

PEKING UNIVERSITY SHENZHEN HOSPITAL
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.(i) patients with initial M protein positivity; 2.(ii) have been tested for free light chain (sFLC), TP, ALB, globulin, ß2-MG, Crea and Hb; 3.(iii) have signed informed consent and are in the sample bank.

Exclusion criteria

Exclusion criteria: 1.(i) data from the same patient; 2.(ii) incomplete data elements and no remaining samples.

Design outcomes

Primary

MeasureTime frame
Free light chain (sFLC), TP, ALB, globulin, ß2-MG, Crea, Hb;—

Countries

China

Contacts

Public ContactAnping Xu

PEKING UNIVERSITY SHENZHEN HOSPITAL

xuanping0528@aliyun.com+86 13510331836

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026